Henrik Elofsson
Geen lopende functies
Profiel
Henrik Elofsson is the founder of Arterion AB, which was founded in 2007.
He held the title of Vice President & Research Manager from 2010 to 2013.
Mr. Elofsson also worked as the Chief Operating Officer at Mendus AB.
Mr. Elofsson received his undergraduate degree from the University of Linköping and his graduate degree from Chalmers School of Entrepreneurship.
Eerdere bekende functies van Henrik Elofsson
| Bedrijven | Functie | Einde |
|---|---|---|
| MENDUS AB | Operationeel Directeur | - |
Arterion AB
 Arterion AB BiotechnologyHealth Technology Arterion AB is a holding company that manufactures biomaterials, including artificial blood vessels, consisting of microbial derived cellulose for revascularization of patients with cardiovascular diseases. It focuses on pure uncoated cellulose grafts as replacement of human vessels, primarily as bypass grafts. Its manufacturing method is based on a novel technology that controls the life conditions of the microbe Gluconacetobacter xylinus. Its use of microbial derived cellulose will allow clinicians to use artificial blood vessels as replacement for vessels with an internal diameter of less than five millimeters. The company was founded on January 4, 2007 and is headquartered in Gothenburg, Sweden. | Oprichter | - |
Opleiding van Henrik Elofsson
| University of Linköping | Undergraduate Degree |
| Chalmers School of Entrepreneurship | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| MENDUS AB | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Arterion AB
Arterion AB BiotechnologyHealth Technology Arterion AB is a holding company that manufactures biomaterials, including artificial blood vessels, consisting of microbial derived cellulose for revascularization of patients with cardiovascular diseases. It focuses on pure uncoated cellulose grafts as replacement of human vessels, primarily as bypass grafts. Its manufacturing method is based on a novel technology that controls the life conditions of the microbe Gluconacetobacter xylinus. Its use of microbial derived cellulose will allow clinicians to use artificial blood vessels as replacement for vessels with an internal diameter of less than five millimeters. The company was founded on January 4, 2007 and is headquartered in Gothenburg, Sweden. | Health Technology |
